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Background: Severe borderline personality disorder is associated with a very high psychosocial and economic
burden. Current treatment guidelines suggest that several manualized treatments, including day hospital
Mentalization-Based Treatment (MBT-DH), are effective in these patients. However, only two randomized controlled
trials have compared manualized MBT-DH with treatment as usual. Given the relative paucity of data supporting the
efficacy and cost-effectiveness of MBT-DH, the possible influence of researcher allegiance in one of the trials, and
potential problems with the generalization of findings to mental health systems in other countries, this multi-site
randomized trial aims to investigate the efficacy and cost-effectiveness of manualized MBT-DH compared to
manualized specialist treatment as usual in The Netherlands.
Methods/design: The trial is being conducted at two sites in The Netherlands. Patients with a DSM-IV-TR diagnosis
of borderline personality disorder and a score of ≥ 20 on the Borderline Personality Disorder Severity Index were
randomly allocated to MBT-DH or treatment as usual. The MBT-DH program consists of a maximum of 18 months’
intensive treatment, followed by a maximum of 18 months of maintenance therapy. Specialist treatment as usual is
provided by the City Crisis Service in Amsterdam, a service that specializes in treating patients with personality
disorders, offering manualized, non-MBT interventions including family interventions, Linehan training, social skills
training, and pharmacotherapy, without a maximum time limit. Patients are assessed at baseline and subsequently
every 6 months up to 36 months after the start of treatment. The primary outcome measure is the frequency and
severity of manifestations of borderline personality disorder as assessed by the Borderline Personality Disorder
Severity Index. Secondary outcome measures include parasuicidal behaviour, symptomatic distress, social and
interpersonal functioning, personality functioning, attachment, capacity for mentalizing and quality of life.
Cost-effectiveness is assessed in terms of the cost per quality-adjusted life year. Outcomes will be analyzed using
multilevel analyses based on intention-to-treat principles.
Discussion: Severe borderline personality disorder is a serious psychological disorder that is associated with high
burden. This multi-site randomized trial will provide further data concerning the efficacy and cost-effectiveness of
MBT-DH for these patients.
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Cost-effectivenessBackground
Borderline Personality Disorder (BPD) is one of the most
prevalent mental disorders [1]. In the general population 1
to 2% of adults are diagnosed with BPD. In psychiatric
populations up to 10% of outpatients and 20% of inpa-
tients are diagnosed with BPD [1,2]. BPD is also associated
with high psychosocial and socio-economic costs [3,4].
The economic burden of disease associated with BPD is
higher than that associated with depression, and compar-
able to that of patients with schizophrenia [1,4]. BPD is
also associated with high psychiatric comorbidity, particu-
larly depression, anxiety disorders, eating disorders, sub-
stance abuse [5-7] and various other personality disorders
[5,6,8-13], often in combination with high levels of acting-
out (e.g., suicidality) [14] and/or functional impairment
[15-17]. The lifetime risk for completed suicide associated
with BPD may be as high as 10% [14]. Together, these
findings emphasize the need for the development of ef-
fective treatments for this severe disorder.
In recent years, a number of evidence-based specialist
treatments for BPD have been developed and evaluated
[1]. These include dialectical behaviour therapy [18],
schema therapy [19], transference-focused psychotherapy
[20,21], Systems Training for Emotional Predictability and
Problem Solving (STEPPS) [22], and Mentalization-Based
Treatment (MBT) [23]. Various reviews [1,24,25] and
treatment guidelines [26-28] recommend these treatments
for patients with BPD.
The present study focuses on MBT as developed by
Bateman and Fonagy in the United Kingdom [23,29,30].
MBT is a promising psychodynamic treatment that is
rooted in attachment and mentalizing approaches.
Briefly, mentalizing refers to the capacity to interpret the
self and others in terms of internal mental states such as
feelings, emotions, wishes, desires, attitudes and values.
This capacity is typically acquired in attachment rela-
tionships, and is associated with feelings of self-agency,
affect regulation and resilience in the face of adversity. A
growing body of research suggests that impairments in
mentalizing can be seen as a core feature of BPD, as pa-
tients with BPD typically fail to make sense of their own
internal experiences and those of others, particularly in
contexts characterized by high levels of arousal. This re-
sults in emotional instability, impulsive behaviour, and
the use of self-defeating strategies in an attempt to cope
with these feelings (such as self-harm, substance abuse
and promiscuity).So far, two types of MBT have been empirically investi-
gated: intensive outpatient MBT (MBT-IOP) [29] and day
hospital MBT (MBT-DH). Both MBT-IOP and MBT-DH
consist of a treatment phase and a maintenance phase, each
lasting a maximum of 18 months. The treatment phase of
MBT-DH, the focus of the current study, consists of a day
hospital treatment (five days per week) that includes daily
group psychotherapy, weekly individual psychotherapy, in-
dividual crisis management from a mentalizing perspective,
art therapy twice a week, mentalizing cognitive therapy and
writing therapy. The maintenance phase in MBT-DH con-
sists of a one-day follow-up treatment program combined
with intermittent individual follow-up appointments, with
the frequency reduced over time (step down).
At the time the current study was designed (2007), there
was only one randomized controlled trial (RCT) investi-
gating the efficacy and cost-effectiveness of MBT-DH
compared to treatment as usual (that is, standard psychi-
atric care) conducted by the developers of MBT [31].
This study randomized 38 BPD patients to either MBT-
DH or TAU, which consisted of standard treatment
offered in the UK in general psychiatric services and com-
prised (a) regular psychiatric review with a senior psych-
iatrist when necessary (on average twice a month); (b)
inpatient admission when necessary, with discharge to
non-psychoanalytic psychiatric partial hospitalization fo-
cusing on problem solving; followed by (c) outpatient and
community follow-up as standard aftercare [31]. Results
showed that MBT-DH was superior to TAU on all major
outcome variables, that is, depressive symptoms, suicide
attempts and self-harm, number of inpatient days, and so-
cial and interpersonal functioning. These results were
maintained during the 18-month follow-up period [32].
Five years after discharge from MBT, the MBT-DH group
still showed superiority over TAU on suicidality, diagnos-
tic status, service use, use of medication, global function-
ing scores above 60 (on the Global Assessment of
Functioning [GAF] Scale), and vocational status [33]. For
example, 74% of the patients in the TAU condition had
made at least one suicide attempt, in comparison with
only 23% in the MBT-DH group. And at the end of the
follow-up period, 13% of the MBT-DH patients met the
diagnostic criteria for BPD, compared to 87% of the TAU
group. Before treatment the total health related-costs for
the MBT-DH group ($44,947) and the TAU group
($52,563) were comparable; after 18 months of treatment
the costs were reduced to $27,303 in MBT-DH and
Laurenssen et al. BMC Psychiatry 2014, 14:149 Page 3 of 13
http://www.biomedcentral.com/1471-244X/14/149$30,976 in TAU. During the 18-month follow-up, costs
further diminished sharply. After 18 months follow-up,
the total health-related costs in the MBT-DH group were
one-fifth of that for patients in the TAU condition: $3,183
for MBT-DH compared to $15,490 for TAU [32].
Since this original trial, two other trials focusing on
MBT-DH have been published. An RCT in Denmark in-
vestigated the efficacy of MBT-DH compared with a less
intensive manualized supportive group therapy com-
bined with psycho-education and medication treatment
in patients diagnosed with BPD [34]. In total, 58 patients
were randomly allocated to MBT-DH and 27 patients to
the specialist combined treatment. Results showed that
both the intensive combined MBT treatment and the
less-intensive supportive group therapy led to significant
improvements on a variety of psychological and inter-
personal measures, e.g., general functioning, depression,
social functioning and number of diagnostic criteria met
for BPD, with moderate to large effect sizes (d = 0.5 to
2.1). Contrary to the expectations of the researchers,
however, MBT-DH was superior only on therapist-rated
GAF [34]. No follow-up or cost-effectiveness data are
yet available from this trial.
Additional evidence for the effectiveness of MBT-DH
comes from a naturalistic study by Bales and colleagues
[35] in The Netherlands. These authors investigated the ef-
fectiveness of 18-months of manualized MBT-DH in 45
patients with severe BPD and a high prevalence of comor-
bid Axis-I and Axis-II disorders. Results showed significant
improvements in symptomatic distress, social and interper-
sonal functioning, and personality pathology and function-
ing; with moderate to large effect sizes (d = 0.7 to 1.7).
These authors also showed that care consumption, defined
as additional treatments and admissions during the last
year before entry into and during MBT treatment, reduced
significantly during and after treatment. Yet, the lack of a
control group limits the possibility to draw conclusions
from this study about the effectiveness of MBT-DH.
Hence, although there is some promising evidence sup-
porting the efficacy and cost-effectiveness of MBT-DH,
given the small number of studies, more research is ur-
gently needed, particularly in light of the limitations of
existing trials. First, one of the two RCTs was conducted
by the developers of MBT [31], and thus researcher alle-
giance may have influenced this study. Second, it is un-
clear whether results from trials conducted in the UK and
Denmark may generalize to The Netherlands, given the
large differences in health care systems between these
countries. For instance, standard psychiatric care may
be more effective in The Netherlands than in the UK be-
cause of differences in the allocation of health care and
the clinical training of health workers. For instance, stand-
ard care in the Netherlands includes more and thus more
expensive evidence-based treatments compared to theUK, and there is more funding available per patient. This
assumption leads to the expectation that differences be-
tween a specialist treatment such as MBT-DH and TAU
may be smaller in The Netherlands, as they may be in
Denmark, which may explain the lack of substantial differ-
ences between MBT and specialist standard care in the
trial of Jørgensen et al [34]. This assumption is supported
by recent findings that highly structured treatment pro-
grammes are associated with considerable effects in BPD
patients, which are often comparable to the effects of spe-
cialist treatments such as MBT [33,34,36]. For instance, in
a randomized trial of BPD patients, Bateman and Fonagy
[29] found that MBT-IOP outperformed a manualized
structured clinical management programme only at long-
term follow-up in terms of effects on suicide attempts, se-
vere incidents of self-harm, symptom severity, depression,
interpersonal functioning and social adjustment. Hence,
with regard to generalizability, a concern is the need for
trials comparing MBT-DH to a credible TAU [29].
Further, the study by Jørgensen and colleagues [34]
suffered from a number of important methodological
limitations, such as a skewed randomization (with the
majority of patients being randomized to MBT-DH) and
the fact that the same therapists conducted treatments
in both conditions (i.e., MBT-DH and supportive ther-
apy), which may have led to “spill-over” effects.
Finally, none of the existing trials focused on the pur-
ported mechanism of change in MBT, that is, changes in
attachment and mentalizing. Given the growing evidence
for the role of common factors in psychotherapy, there
is a pressing need to provide evidence for presumed
mechanisms of change in current evidence-based treat-
ments such as MBT [37].
Research aims and hypotheses
The primary aim of the present study was to investigate
the efficacy and cost-effectiveness of MBT-DH in com-
parison to a specialist TAU in The Netherlands. We ex-
pect both MBT-DH and specialist TAU to be effective
on both primary and secondary outcomes. Yet, we ex-
pect MBT-DH to outperform TAU, particularly at
36 months follow-up. After 18 months of treatment we
expect the costs in the MBT programme to be compar-
able to TAU; after 36 months we expect MBT-DH to
outperform TAU (following Bateman & Fonagy [32]).
Second, we will investigate purported mechanisms of
change in MBT, focusing on changes in attachment and
mentalizing. Results of this trial are expected to inform
mental health professionals, patients, and policy makers.
Methods/design
Design
This study is a multi-site RCT comparing the efficacy
and cost-effectiveness of manualized MBT-DH and a
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inclusion of patients started in March 2009 and ended in
July 2012. The last follow-up measurement, at 36 months,
will be in July 2015. Two mental health care centres agreed
to participate in this study: Arkin en De Viersprong, both
located in Amsterdam. Arkin is a large mental health
care centre that specializes in the treatment of BPD.
De Viersprong is a national institute for personality prob-
lems, offering specialized outpatient, day hospital, and in-
patient psychotherapy for adolescent and adult patients
with severe personality problems and disorders. Arkin
agreed to run four MBT-DH groups and De Viersprong
agreed to run two MBT-DH groups in the context of the
trial, each consisting of nine patients. The City Crisis
Service, which is part of Arkin, agreed to run the specialist
TAU condition. The overall aim was to randomize 54 pa-
tients to MBT-DH and 54 patients to TAU.
Ethics
A certified Medical Ethics Review Committee in The
Netherlands has approved this study, registered under
NL38571.078.12. This ethical approval covered all sites
of data collection.
Participants
Patients were referred for treatment by general practi-
tioners, mental health care institutions, private practices
and general hospitals. Inclusion criteria were (a) a BPD
diagnosis as measured by the Structured Clinical Interview
for DSM-IV Axis II Personality Disorders (SCID-II) [38]
and (b) a total score on the Borderline Personality Disorder
Severity Index (BPDSI) [39] of at least 20, reflecting severe
BPD. Originally, a BPDSI score ≥ 25 was proposed as a cut-
off point. However, it became clear quickly that this criter-
ion was overly strict, as several patients who did not meet
this criterion showed severe functional impairments.
Hence, we decided to adopt a cut-off of 20. Exclusion cri-
teria were kept to a minimum to ensure generalizability
and to allow patients with severe BPD to be included. The
exclusion criteria were: (a) the presence of an Axis-I dis-
order (as determined with the Structured Clinical Interview
for DSM-IVAxis I Personality Disorders (SCID-I) [40]) that
required specialist treatment, (b) organic brain disorder, (c)
IQ below 80, and (d) inadequate mastery of the Dutch
language.
Procedure
All patients referred to one of the mental health care insti-
tutes were invited to attend an intake appointment. Patients
who were deemed eligible received more information about
the study and, if they were interested, a new appointment
was set during which the BPSDI [39], and SCID-II [38]
interviews were administered and other eligibility criteria
were assessed. If patients met inclusion criteria, theyprovided informed consent and were randomized to either
MBT or TAU by an independent researcher using a com-
puterized 1:1 algorithm. Patients were subsequently asked
to complete the baseline measures (see Figure 1). It was
preferred that patients completed the measures in the
clinic; however if patients insisted, they were allowed to
complete questionnaires at home, in which case patients
were asked to return the questionnaires within a week by
regular mail.
After baseline assessments, patients are assessed at 6,
12, 18, 24, 30 and 36 months after the start of treatment.
At these time points, patients complete a battery of
questionnaires and interviews. In addition, at 36 months,
the SCID-I [40], SCID-II [38], BPDSI [39], the Substance
use section of the Measurements in the Addictions for
Triage and Evaluation (MATE) [41] and the Suicide and
Self-Harm Inventory (SSHI) [23] are readministered by
research assistants (MSc-level psychologists) who are
blind to treatment condition. Patients are invited by tele-
phone to come to the clinic to complete these assess-
ments. If they do not respond or fail to attend the first
appointment, up to three attempts are made to contact
them by telephone to remind them. If patients refuse to
complete the questionnaires at the clinic, they are
allowed to complete them at home and return them by
regular post; in this case, the SCID-I, SCID-II, BPDSI,
MATE and SSHI can be completed over the telephone.
Treatments
Day hospital MBT
MBT-DH is an intensive, manualized specialist treatment
for patients with BPD that has been described in detail else-
where [23,35]. Briefly, MBT-DH in this study consists of an
intensive day-hospitalization programme of 18 months
followed by a maximum of 18 months of maintenance
mentalizing (group) therapy. The day-hospital program,
covering five days per week and 4.5 hours per day, includes
the following components: (a) implicit mentalizing groups
(i.e., daily group psychotherapy and weekly individual psy-
chotherapy, and individual crisis planning from a mentaliz-
ing perspective) and (b) explicit mentalizing groups (i.e., art
therapy twice a week, mentalizing cognitive group therapy,
and writing therapy). The week’s program is ended by a so-
cial hour and a community meeting. Patients can also con-
sult a psychiatrist once a week and medication is offered
following American Psychiatric Association guidelines.
The treatment goals of MBT-DH are: (a) to engage the
patient in treatment; (b) to reduce psychiatric symptoms,
particularly self-harm and parasuicidal behaviour; (c) to
improve social and interpersonal functioning; and (d) to
foster more appropriate health care usage and prevent hos-
pital admissions and prolonged inpatient care. To achieve
these goals, components of the programme focus on en-
hancing the capacity for mentalizing.
Figure 1 Expected patient enrolment in the study.
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cing their mentalizing capacity, particularly in high
arousal contexts, patients will show improvements in
understanding themselves and others, leading to a de-
creased need to rely on maladaptive coping strategies to
deal with feelings of inner emptiness and “badness”, im-
pulsivity and relationship conflicts.
The MBT teams consist of a total of three certified and
registered psychologists, two psychotherapists, one psych-
iatrist, four sociotherapists, and a creative therapist. All cli-
nicians who are involved in providing MBT-DH followed
an MBT training programme led by a certified MBT
trainer in The Netherlands, who also acted as a consultant
before and during the study and provided supervision in
the initial stages of the trial.Adherence to the MBT treatment model is monitored
in the following ways. First, in daily group reflections
after the group therapy, therapists are stimulated to
reflect on their adherence to the treatment model.
Specifically, therapists are asked to reflect on whether
their interventions have enhanced mentalizing, which
interventions have not, and what alternative interven-
tions might have been more successful. Second, every
6 months therapists complete, with regard to their own
interventions and those of their co-therapist, the MBT
Adherence and Competence Scale [42] for five con-
secutive days within one week after a group therapy
session. Third, during team supervision (every 2 weeks),
adherence to the treatment model is addressed using
case material.
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As noted, TAU is based on a manualized treatment for se-
vere personality disordered patients [43]. When possible,
patients in the TAU condition are treated by the City Crisis
Service itself. When more specific treatment is needed
(e.g., treatment for drug addiction or hospitalization),
other treatment centres are sought as appropriate for pa-
tients’ specific needs. Additionally, if patients prefer to be
treated in the area where they live, the intaker or crisis
team aims to find an appropriate treatment for them in
their own environment.
The City Crisis Service is specialized in providing
emergency assistance and long-term aftercare treatment
after crises and is composed of five psychiatrists, two
psychologists, five mental health nurses and one system
therapist. Treatment is mainly provided on an outpatient
basis; day treatment or hospitalization is offered only
when necessary. The team aims to deliver optimal care
by matching the intensity of one or more interventions
with the need of the patients. Interventions consist of
supporting and structuring sessions, extensive diagnostic
investigations, writing a crisis plan, family interventions,
STEPPS [22] or Linehan training, social skills training or
learning how to deal with aggression/impulse control,
cognitive schema-focused or traditional insight-oriented
treatment, pharmacotherapy, and inpatient treatment
when deemed necessary. The outpatient team involved
in the City Crisis Centre has a capacity of 50 patients.
Because of the specialist nature of this service, the fact
that its treatment was manualized, and its extensive ex-
perience with treating patients with BPD, we chose it as
the provider of TAU for the present study. There is no
maximum time limit for treatment. No adherence mea-
sures are available for TAU.
Measurements
Demographic variables
At baseline, participants complete questions concerning
their marital status, living situation, religion, education
level, diploma, current job and working situation, and
questions concerning the main earner in the family (re-
lation to the patient, annual income, occupation, and
source of income).
Primary outcome
The total score on the BPDSI [39] was chosen as the pri-
mary outcome measure. The BPDSI is a semi-structured
interview, developed to assess BPD features as defined by
DSM-III-R/DSM-IV criteria [44,45]. The purpose of the in-
strument is not to diagnose BPD, but to yield a quantitative
index of the current severity of BPD features. The BPDSI
contains the following nine subscales: (a) abandonment,
(b) relationships, (c) identity, (d) impulsivity, (e) parasuici-
dal behaviour, (f) affective instability, (g) emptiness, (h)anger-control, and (i) dissociation and paranoid idea-
tion. The BPDSI has been shown to be sensitive to change
[39]. In a study of BPD patients, patients with other per-
sonality disorders, and patients with only Axis-I disorders,
the BPDSI was highly reliable (intraclass correlation coef-
ficient [ICC] = .93) and internally consistent (Cronbach’s
α = .85).
Secondary outcomes
Symptomatic distress Symptomatic distress is assessed
with the SSHI, the Personality Assessment Inventory-
Borderline (PAI-BOR), the Beck Depression Inventory
(BDI-I), the Brief Symptom Inventory (BSI), the Out-
come Questionnaire (OQ-45), and the MATE.
Suicide and self–harm are assessed with the SSHI [23].
The SSHI is a semi-structured interview assessing (a)
the frequency and severity of suicidal acts in the past
6 months, and (b) the frequency and severity of acts of
self-mutilation in the past 6 months. This interview
poses specific questions not only about the number of
acts but also about the dangerousness of these acts - that
is, the presence or absence of another person at the
time, the likelihood of being found, preparation for the
act, and lethality of the act. Multiple acts over a short
period of time – for example, frenzied self-cutting - are
counted as a single act [31].
The Dutch version of the PAI-BOR [46,47] is part of
the Personality Assessment Inventory [46] and consists
of four subscales (each with six items), which reflect four
characteristics of BPD: affective instability (AI), identity
problems (IP), negative relationships (NR), and self-
harm (SH). There are four response categories (0 = false,
1 = slightly true, 2 =mainly true, and 3 = very true). An
example item is “Sometimes I feel very empty inside”.
According to the manual of the PAI-BOR [46], a total
PAI-BOR raw score of 38 or more indicates the presence
of significant BPD features, whereas a score of 60 or
more indicates typical borderline personality function-
ing. The internal consistency (Cronbach’s α) of the
Dutch PAI-BOR is good (α = .81) and 6-month test-
retest correlation is .78 [47].
The BDI-I is used to assess depressive symptoms
[48]. The BDI-I is a self report instrument, which con-
sists of 21 questions concerning depressive symptoms
during the last week. Each question has a set of four
possible answers, ranging in intensity from 0 to 3, for
example, “I don’t feel sad” (0) to “I feel so sad or un-
happy that I cannot bear it anymore” (3). The total
scores are categorized: 0–9 no depression, 10–18 mild-
moderate depression, 19–29 moderate-severe depres-
sion and 30–63 severe depression. The BDI-I has been
shown to have high internal consistency (α > .80) is one
of the most commonly used instruments to assess se-
verity of depression [49].
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the Dutch version of the BSI [50,51]. The BSI is the short
version of the Symptom Checklist-90. It consists of 53
items covering nine symptom dimensions (somatization,
obsession-compulsion, interpersonal sensitivity, depres-
sion, anxiety, hostility, phobic anxiety, paranoid ideation,
psychoticism) and yields three global indices of distress:
Positive Symptom Distress Index, Positive Symptom Total,
and Global Severity Index (GSI). Possible GSI scores range
from 1 to 5, with higher scores indicating a higher level of
psychological and emotional distress. Respondents have to
rate each feeling item (e.g., “your feelings being easily
hurt”) on a five-point scale ranging from 0 (not at all) to 4
(extremely), representing the intensity of distress during
the past 7 days. Reliability of the Dutch version is good
(Cronbach’s α ranging from .71 to .85) and the factor
structure is comparable to that of the original versions of
Derogatis [51].
The OQ-45 [52,53] was developed to capture three
domains central to mental health: symptom distress,
interpersonal relations and social role functioning. This
self-report questionnaire consists of 45 items to be rated
on a five-point Likert scale ranging from 0 (never) to 4
(almost always). Reliability and validity of this instru-
ment have been demonstrated [52,53].
The substance use section of MATE [54] is used to as-
sess substance abuse and dependency. This section,
which is designed as an interview, asks about the use of
psychoactive substances in the past month and during
the lifetime. The interviewer in this study was an MSc-
level psychologist. The inter-rater reliability ranges be-
tween 0.75 and 0.92 [55].
Social and interpersonal functioning The Inventory of
Interpersonal Problems (IIP-64) is used to assess inter-
personal problems [56]. It is a self-report measure con-
sisting of 64 items assessing eight dimensions of
interpersonal problems: (1) domineering/controlling (e.g.,
“It is hard for me to take instructions from people who
have authority over me”), (2) vindictive/self-centred (“It is
hard for me to trust other people”), (3) cold/distant (“It is
hard for me to show affection to others”), (4) socially
inhibited (“It is hard for me to introduce myself to some-
one”), (5) non-assertive (“It is hard for me to be firm when
I need to be”), (6) overly accommodating (“It is hard for
me to be angry at others”), (7) self-sacrificing (“It is hard
for me to be angry at someone I like”) and (8) intrusive/
needy (“It is hard for me to be on my own”). Respondents
are asked to consider each problem and to rate how
distressing that problem has been on a scale ranging from
0 (not at all) to 4 (extremely). The IIP-64 possesses good
psychometric properties, with Cronbach’s α of .96 for
the total score and a test-retest reliability coefficient of
.78 [57].Personality functioning Personality functioning is assessed
with the Severity Indices of Personality Problems – Short
Form (SIPP-SF) and the Dimensional Assessment of
Personality Pathology – Short Form (DAPP-SF).
The SIPP-SF [58] is a dimensional self-report measure
assessing the severity of personality pathology and has
been developed for research purposes. The SIPP-SF aims
to assess the core components of adaptive and maladap-
tive personality functioning. It consists of 60 items, which
cluster into five higher-order domains: (1) self-control, (2)
identity integration, (3) relational capacities, (4) social
concordance and (5) responsibility [59]. The SIPP-SF asks
respondents to think about the past 3 months and to
answer the extent to which they agree with statements
such as “I frequently say things I regret later”. Items are
rated on a four-point Likert type scale ranging from 1
(fully disagree) to 4 (fully agree). High scores on the do-
mains indicate better functioning. The SIPP-SF is a short-
ened version of the SIPP-118, which has good reliability
(Cronbach’s α ranging from .62 to .89, M = .78) [59].
The DAPP-SF consists of 136 of the original 290 items
of the DAPP-BQ [60,61]. The 136 items cover 18 per-
sonality disorder trait-based dimensions fitting into four
broad higher order factors: emotional dysregulation, dis-
social behaviour, inhibition and compulsivity [62]. The
items are rated on a five-point Likert scale with scores
ranging from 1 (very unlike me) to 5 (very like me). Both
the DAPP-BQ and the DAPP-SF have good psychomet-
ric features [62].
Attachment and mentalizing Attachment is assessed
with the Experiences in Close Relationships (ECR) question-
naire [63,64] and the Dutch Attachment Style Questionnaire
[65]. Mentalizing is measured using the Reflective
Functioning Questionnaire (RFQ).
The ECR questionnaire [63,64] measures adult attach-
ment in romantic relationships. It contains two sub-
scales, Anxiety about rejection and abandonment (e.g., “I
worry about being abandoned”) and Avoidance of intim-
acy (“I feel very uncomfortable when my partner wants
to have a close connection to me”), both consisting of 18
items. Individuals are asked to rate each statement on a
seven-point Likert scale ranging from 1 (disagree strongly)
to 7 (agree strongly).
The Dutch Attachment Style Questionnaire [65] is a
measure of attachment to others in general (and thus
not to a specific person as is the case for the ECR). The
questionnaire consists of 24 items and measures the fol-
lowing four attachment styles defined by Bartholomew
and Horowitz [66]: (1) secure attachment, consisting of
eight items (e.g., “I trust others to be there when I need
them”), (2) avoidant attachment, consisting of five items
(e.g., “It is important for me to be independent”), (3)
preoccupied attachment, consisting of seven items (e.g.,
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better than they like me”) and (4) anxious attachment
style, consisting of four items (e.g., “I am afraid that
others will betray me when I become too close to
them”). All items are scored on a five-point Likert scale
ranging from 1 (strongly disagree) to 5 (strongly agree).
The internal consistency ranges from .61 (Avoidant)
to .86 (Preoccupied) [65].
The RFQ [67] consists of 57 items with ratings on a
seven-point scale (1 = Strongly disagree, 7 = Strongly
agree). An example of a statement is “It costs me a lot of
time to understand the thoughts and feelings of other
people”. The internal consistency of the RFQ is good
(α = .77) and the test-retest reliability is high (α = .78) [67].
Quality of life Quality of life is measured using the
EuroQol EQ-5D-3 L [68]. This self-report questionnaire
provides a simple method to capture health problems
according to a five-dimensional classification: mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. Each dimension is divided into three levels:
no problem, moderate problems, extreme problems. The
five dimensions can be summarized into a “value”, based
on the preferences of the general public. These values
can be used as societal weights for the calculation of
quality-adjusted life years (QALYs) in health economic
evaluations (see also below). To calculate these societal
weights, we will use a Dutch validation study [69,70].
Next to the five dimensions, the EuroQol presents a ver-
tical visual analogue scale, ranging from 0 (worst imagin-
able health) to 100 (best imaginable health). The values
are seen as representing patients’ values, in contrary to
the societal weight based on the five dimensions. The re-
liability of the EQ-5D-3 L has been investigated and
found to be acceptable [71] and it has shown to be sensi-
tive to change in patients with personality disorders
[4,72].
Mental-health-related functional impairment The
Sheehan Disability Scale (SDS) [73] was developed to as-
sess functional impairment in three inter-related do-
mains: work/school, social and family life. It is a brief
self-report tool consisting of four questions. The patient
rates the extent to which work/school, social life and
home life or family responsibilities are impaired by his
or her symptoms on a 10-point visual analogue scale. An
example question is: “I do not function well at work be-
cause of my problems”. The internal consistency of the
SDS total score is good (Cronbach’s α = .89) and test-
retest reliability for the SDS total score is acceptable
(ICC = .73) [74].
DSM-IV Axis-I and Axis-II-diagnoses The SCID-I
[40,75] is used to diagnose Axis I disorders at intake andat 36 months follow-up. The SCID-II [38,76] is used for
diagnosing Axis II personality disorders at intake and at
36 months follow-up. The interviewer is an MSc-level
psychologist, who was trained by an expert trainer in the
SCID-II. No interrater reliability data were collected in
this study. Previous research has shown, however, that
the SCID-II has good interrater reliability and test-retest
interrater reliability in adults [77,78].
Patient adherence to the treatment Patients’ adher-
ence to the treatment is derived from the realized dose.
The clinical staff record the type, number, and duration
of all attended sessions and the number of missed ses-
sions and reason for absence. Based on this information,
we will calculate the proportion of missed sessions as a
quantitative index of treatment adherence.
Costs The intervention costs of MBT-DH and TAU are
calculated using a mixture of top-down and bottom-up
approaches. The intervention costs estimates will include
personnel costs, implementation costs (e.g., hosting and
coaching) and any other overhead costs associated with
the treatment. Medical costs beyond the intervention
costs of MBT-DH and TAU are calculated using the Trim-
bos and Institute for Medical Technology Assessment
(iMTA) Questionnaire on Costs Associated with Psychi-
atric Illness (TiC-P: [79]). The TiC-P will be used to meas-
ure health care utilization at baseline and after 6, 12, 18,
24 and 36 months.
The first part of the TiC-P consists of questions on (1)
the number of visits to, e.g., a general practitioner,
psychiatrist (outside TAU or MBT-DH), medical special-
ist, physiotherapist or alternative health practitioner; (2)
the day care/hospital lengths of stay (outside TAU or
MBT-DH); and (3) the use of medication in the 4 weeks
prior to filling out the questionnaire. These values are
multiplied with unit prices of the corresponding health
care services according to the Dutch manual for costing
studies in health care [80]. The unit prices for 2010 will
be adjusted to 2014 prices using the Consumer Price
Index [81]. As the mean direct costs are measured per
4 weeks, we will multiply these values by 13 to estimate
the annual costs.
The TiC-P also asks the patient to report any product-
ivity losses, that is, absence from work or reduced
productivity at work. This report is used to estimate the
so-called “friction costs”: the monetary representation of
the replacement of the labour. The friction-cost method
takes the employer's perspective, and counts as lost only
those hours not worked until another employee takes
over the patient's work. This is a more conservative esti-
mate than the so-called “human capital method”, which
relates productivity costs one-to-one to the labour costs
of the patient. The choice between friction costs and
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mists. In this study, we chose the more conservative
friction-cost method [82].
Questionnaires completed by therapists
Therapists complete questionnaires at 6, 12, 18, 24, 30
and 36 months after the start of treatment of each pa-
tient regarding treatment alliance, functional impairment
of the patient, the Clinical Global Impression scale
(CGI) and medication adherence.
Treatment alliance The Helping Alliance Questionnaire
(HAQ) is based on two types of “helping alliance”. Type
I is about the experience of the therapist supporting and
helping the patient. Type II is about the experience of
joint collaboration [83]. Luborsky and colleagues ex-
panded the original HAQ from 11 to 19 questions [84].
There is both a patient and a therapist version, but in
this study only the therapist version is used. Items are
rated on a six-point Likert scale (1 = I strongly feel it is
not true; 6 = I strongly feel it is true). An example ques-
tion is “My patient believes I’m experienced”. The total
score is the mean of the item scores. The HAQ-II shows
good internal consistency (α ranging from .90 to .93)
[85] and test-retest reliability (.56) [84].
Functional impairment of the patient We adapted the
SDS [73] so that therapists can rate the functional im-
pairment of the patient in three domains: work/school,
social and family life.
Clinical global impression The CGI [86] provides a
summary of an individual’s clinical functioning as assessed
by the therapist. The CGI consists of two ratings: Severity
of Illness (CGI-S) at the moment of contact, and Global
Improvement (CGI-I) of the patient since the start of
treatment. Both use a seven-step categorical scale: for the
CGI-S, ranging from 0 (normal, not at all ill) to 7 (among
the most extremely ill patients), and for the CGI-I, from 0
(very much improved) to 7 (very much worse).
Sample size and power calculation
Based on records of 2008, we estimated the number of
new referrals per year to Arkin and De Viersprong. On
average, the total annual number of new referrals was
265 at De Viersprong and 230 at Arkin. Out of all newly
referred patients, 154 suffered from a severe BPD and
met the inclusion criteria for this study. Assuming a re-
fusal rate of 35%, this means that on average 8.1 patients
could be included each month. Therefore, we expected
to be able to recruit and assess 108 patients (54 in
each arm) during a recruitment window of 14 months.
Figure 1 shows the expected flow of participants from
recruitment through the beginning of the study.In this study the primary clinical outcome variable is
the total score on the BPDSI, an index of the severity of
BPD manifestations. Bales and colleagues [35] found a
large effect size of 1.23 on the BPDSI after 18 months of
MBT-DH, in a sample of 45 BPD patients. Although
Bateman and Fonagy [33] used another index for the
severity of borderline symptoms (the Zanarini Rating
Scale for Borderline Personality Disorder, a clinician-
administered scale for the assessment of change in
DSM-IV borderline psychopathology [87]), they also
found a large effect size 5 years after MBT (a difference
of 64% between TAU [mean = 15.1, SD = 5.3) and MBT-
DH [mean = 5.5, SD = 5.2; effect size = 1.8]). Although
within-group effect sizes for MBT can be expected to be
large, the specialist TAU investigated in the present
study may be more effective than TAU provided in the
UK. Yet, given differences in effect sizes in previous tri-
als, particularly in the long term, we expect MBT-DH
patients to improve at least 20% more than TAU pa-
tients on the BPDSI at 18 months after the start of the
intervention. With a sample of 54 patients per group, an
effect size of at least .65 on the BPDSI could be detected
with a power of 92% (α = .05, β = .083), which reflects a
reasonable, realistic and clinically relevant effect.
Statistical analyses
First, to investigate potential differences between the
two groups at baseline, we will use parametric and non-
parametric descriptive statistics, as appropriate. For the
main analyses concentrating on primary and secondary
outcomes, linear growth curve models for normally dis-
tributed outcome measurements will be used, logistic re-
gression for binary data, and Poisson regression models
for ordinal data. Results will be expressed in terms of
comparison of the slopes for interval data, odds ratios
for binary data and incidence rate ratios for ordinal data.
Furthermore, we will perform explorative analyses re-
garding mechanisms of change using both variable and
person-centered approaches. All analyses will be con-
ducted according to intention-to-treat principles.
Health economic evaluation
We will estimate the difference in total costs for MBT-
DH compared to TAU and the difference in clinically
relevant effects of the treatments. By dividing the differ-
ence in costs by the difference in effectiveness, the incre-
mental cost-effectiveness ratio (ICER) will be estimated.
The ICER represents the extra amount of money that
has to be invested or will be saved to gain or lose on
extra unit of effect.
In the economic evaluation, all relevant costs and ef-
fects will be taken into account, meaning that we will
use a so-called societal perspective, which is preferred in
economic evaluations in The Netherlands [88]. The
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costs, direct and indirect medical costs, as well as prod-
uctivity losses and costs made elsewhere in the health
care system. Using the societal perspective, clinically
relevant effects are those effects that are meaningful for
society. Moreover, in order to compare effects between
allocations in health care, effects should be expressed in
generic terms. We will therefore use QALYs and will ex-
press the cost-effectiveness and its ratio as cost per
QALY. The use of QALYs is advised in guidelines for
cost-effectiveness analysis, especially when main effects
are expected in quality of life [89].
Our primary cost-effectiveness ratio will be estimated
using empirical data only and therefore using a 3-year
time horizon, which is equal to the trial duration. Cost
data are generally highly skewed, and QALY scores and
ICER values are not distributed normally in most cases.
Therefore, the uncertainty intervals around the mean
costs, mean effects and mean ICER values will be esti-
mated using bootstrap simulations with 1000 replica-
tions [90-92]. These results will be graphically presented
in cost-effectiveness planes. Various societal willingness-
to-pay values will be used to estimate net monetary
benefits. These net monetary benefits are then used to
derive cost-effectiveness acceptability curves.
We will also explore the long-term costs and effects of
MBT-DH and TAU from a societal perspective. One way
of achieving this would be to use a Markov model to ex-
plore the long-term cost-effectiveness of the intervention
under study. However, health stages in a Markov model
are often predefined, discrete stages, where they should
reflect the biological or theoretical understanding of the
condition being modelled [93,94]. Because in this trial
the BPDSI, which is a continuous measure, is the pri-
mary outcome measure, it does not allow for an unam-
biguous definition of health states to model disease
progression. Having heterogeneous health states may be
controversial, as it means that a wide range of patients
may be clustered in one health state. In order to explore
the cost-effectiveness using a Markov model in our
study, we will therefore define health states on the basis
of a cut-off score on one of the outcome measures such
as the BPDSI or the OQ-45. We will extend the cost-
effectiveness model results after the duration of the trial
using different assumptions based on, for example, the
literature. Sensitivity analysis will be performed in order
to investigate the influence of those assumptions on the
model results.
Discussion
Although MBT-DH is a promising psychodynamic treat-
ment for BPD [1,24-28], so far only two RCTs have com-
pared MBT-DH to specialist TAU [31,34]. Given the
relative paucity of data supporting the efficacy and cost-effectiveness of MBT-DH, the possible influence of re-
searcher allegiance in one of the trials [31], potential
spill-over effects in another trial [34], and problems with
the generalization of findings to mental health systems
in other countries, more research is urgently needed.
Further, the only health economic study of MBT-DH did
not use state-of-the-art cost-effectiveness methodologies
[32]. To assess the efficacy and cost-effectiveness of
MBT-DH in The Netherlands, the current study aims to
compare MBT-DH with specialist TAU using state-of-
the-art cost-effectiveness analyses. Further, because the
current study is a multi-site trial, and treatments in both
treatment arms are conducted by different therapists,
the risk of spill-over effects is minimal.
We expect both MBT-DH and TAU to lead to signifi-
cant reductions in primary and secondary outcome mea-
sures, including symptomatic distress and interpersonal
functioning. However, we expect MBT-DH to outper-
form TAU, particularly at 36 months follow-up.
To date, no studies have examined the purported
mechanism of change in MBT in the context of a ran-
domized trial and there is a pressing need to provide evi-
dence for presumed mechanisms of change in current
evidence-based treatments [37]. Aside from providing
new data on the efficacy and cost-effectiveness of MBT-
DH, this trial also promises to provide a better under-
standing of the mechanisms of change in MBT.
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